LCTX Lineage Cell Therapeutics Inc: Total Debt to Equity Ratio

The Lineage Cell Therapeutics (LCTX) total debt-to-equity chart on GURU.Markets stands at 0.04. The business focuses on treating spinal cord injuries and vision loss, relying on long-term support from allies. Regenerative technologies enable the restoration of lost body tissues. The project is currently in the research stage, meaning cash flow is primarily supported by grants and external financing.

Investors must assess the credit risks of Lineage Cell Therapeutics (LCTX) to understand its capital stability. The development of a cryogenic hub network ensures stable margins and operational resilience for the business. The ratio of total liabilities to equity measures the proportion of borrowed resources within the financing structure. A decline in this metric confirms deleveraging, although excessive conservatism may limit growth rates. A low level of indebtedness guarantees the issuer's financial autonomy.